Rhythm PharmaceuticalsRYTM
RYTM
About: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Employees: 283
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,417% more call options, than puts
Call options by funds: $26.8M | Put options by funds: $1.76M
121% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 24
21% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 53
15% more funds holding
Funds holding: 175 [Q3] → 202 (+27) [Q4]
10% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 11 (+1) [Q4]
3% more capital invested
Capital invested by funds: $3.54B [Q3] → $3.63B (+$90.6M) [Q4]
5.04% less ownership
Funds ownership: 110.64% [Q3] → 105.6% (-5.04%) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$66
1%
upside
Avg. target
$78
20%
upside
High target
$92
41%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Tazeen Ahmad 28% 1-year accuracy 9 / 32 met price target | 4%upside $68 | Buy Maintained | 10 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 331 met price target | 23%upside $80 | Buy Reiterated | 8 Apr 2025 |
Canaccord Genuity Whitney Ijem 34% 1-year accuracy 15 / 44 met price target | 41%upside $92 | Buy Maintained | 8 Apr 2025 |
Needham Joseph Stringer 26% 1-year accuracy 29 / 113 met price target | 1%upside $66 | Buy Reiterated | 8 Apr 2025 |
Wells Fargo Derek Archila 48% 1-year accuracy 15 / 31 met price target | 40%upside $91 | Overweight Maintained | 7 Apr 2025 |
Financial journalist opinion
Based on 9 articles about RYTM published over the past 30 days
Negative
Zacks Investment Research
12 hours ago
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
5 days ago
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
1 week ago
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update.
Positive
Seeking Alpha
3 weeks ago
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmelanotide to the U.S. and EU, for the treatment of patients with acquired hypothalamic obesity, expected in Q3 of 2025. Company pushing forward with oral MC4R-specific agonist to treat patients with acquired hypothalamic obesity known as bivamelagon;
Positive
Zacks Investment Research
3 weeks ago
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
Positive
Zacks Investment Research
3 weeks ago
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Positive
Reuters
3 weeks ago
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial
Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.
Neutral
GlobeNewsWire
3 weeks ago
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p
Neutral
GlobeNewsWire
3 weeks ago
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the Pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.
Neutral
CNBC Television
4 weeks ago
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Charts implemented using Lightweight Charts™